- Company
- Reimb in progress for 1st endometrial cancer immunotherapy
- by Jung, Sae-Im May 30, 2023 05:33am
- Will the latecomer cancer immunotherapy ‘Jemperli (dostarlimab)’ from GSK be reimbursed as the first cancer immunotherapy in endometrial cancer? With cancer immunotherapies changing the treatment paradigm for the first time in decades, the demand in the field to speed up the reimbursement progress has also been increasing. in the field.
- Company
- Ebixa 20mg may be prescribed at general hospitals in Korea
- by Eo, Yun-Ho May 26, 2023 06:47am
- The high-dose formulation of the Alzheimer’s treatment ‘Ebixa’ has landed at general hospitals in Korea. According to industry sources, Lundbeck Korea’s ‘Ebixa (memantine) tablet 20mg’ passed the drug committees of medical institutions in Korea, including Seoul National University Hospital, Seoul Asan Medical Center, Sinchon Severan
- Company
- Lucentis sales fell 34%
- by Chon, Seung-Hyun May 26, 2023 06:47am
- Humira, Avastin, Herceptin, and Mabthera also saw drug prices cut after entering the market for similar drugs. Domestic sales of Lucentis, an eye disease treatment, fell by more than 30%. As Chong Kun Dang and Samsung Bioepis launched biosimilars, drug prices went down and sales took a direct hit. New drugs from multinational pharmaceutical comp
- Company
- Shingles vaccine Shingrix occupies 29% of market in 3 months
- by Jung, Sae-Im May 26, 2023 06:47am
- GSK’s shingles vaccine ‘Shingrix’ occupied 29% of the market in Q1 this year. In only 3 months of its release, it beat MSD’s ‘Zostavax’ and ranked 2nd in the market. The company has made a smooth start by actively conducting marketing activities in partnership with a domestic pharmaceutical company. According to the market research inst
- Company
- BMS’s oHCM drug Camzyos approved in Korea
- by Jung, Sae-Im May 25, 2023 05:46am
- BMS Korea (Country Manager: Hye Young Lee) announced on the 24th that the Ministry of Food and Drug Safety has approved the company’s obstructive hypertrophic cardiomyopathy (oHCM) treatment ‘Camzyos (mavacamten)’ to treat adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy (oHCM)
- Company
- Latecomer new CML drug Bosulif attempts reimb in Korea
- by Eo, Yun-Ho May 25, 2023 05:46am
- The latecomer leukemia treatment ‘Bosulif’ is attempting to receive reimbursement in Korea. According to industry sources, Pfizer Korea submitted an application for its Chronic Myelogenous Leukemia (CML) treatment Bosulif (bosutinib), and is receiving a review for its reimbursement. The drug, which was approved in January in Korea,
- Company
- Seven times stricter standards
- by Chon, Seung-Hyun May 25, 2023 05:46am
- Health authorities have prepared new standards for managing impurities in Januvia, a diabetes treatment. Prior to the release of Januvia generics, pharmaceutical companies were requested to only ship products within the newly set standard. Pharmaceutical companies are busy with quality control by presenting a standard that is seven times str
- Company
- Leading companies in developing new PO microbiome drugs
- by Nho, Byung Chul May 24, 2023 08:28pm
- Recently, the world's first oral microbiome treatment obtained approval from the US Food and Drug Administration (FDA). VOWST from Seres Therapeutics in the U.S. is a drug that prevents re-infection after antibacterial treatment for CDI bacteria for people over 18 years of age. As a new microbiome drug, it is the second after Rebyota of Ferr
- Company
- Pharma industry on alert over business risks in China
- by Lee, Seok-Jun May 24, 2023 05:32am
- Business risks related to China have been rising in Korea’s pharmaceutical industry. There are many causes, including the termination of the contract for supplying medicines (or cosmetics), liquidation of Chinese subsidiaries, and claims for damages, etc. Most of them are due to the failure of their Chinese partners in fulfilling their promises
- Company
- Leclaza posts sales of KRW 25 bil in 2 years in Korea
- by Chon, Seung-Hyun May 24, 2023 05:32am
- Yuhan Corp’s anticancer drug ‘Leclaza’ is making good sales in the Korean market, and raised sales of KRW 5.1 billion in Q1 alone. Its efficacy and safety were confirmed in the real world in actual patients at the time of treatment, and the drug is gradually expanding its market influence ahead of its approval as a first-line treatment. Ac
